Distributor inventory | Tablet
Voglibose 0.3 mg + Repaglinide 0.5 mg (per tablet)
Type 2 diabetes mellitus: to control post‑meal (postprandial) blood glucose in adults when diet and exercise alone or single therapy is inadequate.
Repaglinide stimulates the pancreas to release insulin quickly after meals, lowering blood glucose. Voglibose inhibits intestinal alpha‑glucosidase enzymes, delaying carbohydrate digestion and glucose absorption, thereby reducing post‑meal sugar spikes.
Take by mouth exactly as prescribed. Usually taken shortly (about 15–30 minutes) before meals; if you skip a meal, skip that dose to reduce hypoglycaemia risk. Swallow with water; follow diet/exercise advice and monitor blood glucose as directed.
Common side effects of VOLIBO R 0.3/0.5MG TAB may include:
May cause hypoglycaemia (especially with missed meals, excessive exercise, alcohol, or when used with other antidiabetics); carry glucose. Use caution in liver impairment; monitor liver function. Not recommended in type 1 diabetes or diabetic ketoacidosis. Voglibose can cause significant GI effects; avoid in intestinal obstruction, chronic intestinal disease, or severe digestive disorders. Use caution in elderly and in renal impairment; dose individualization needed. Seek medical help for severe abdominal symptoms, jaundice, or persistent hypoglycaemia.
